We use cookies to improve the performance of our site and optimize it for our users. Customize Cookie Preferences

Sign Up Today and Learn More About Cambridge Epigenetix Stock

Invest in or calculate the value of your shares in Cambridge Epigenetix or other pre-IPO companies through EquityZen's platform.

Get Started

Cambridge Epigenetix Stock (CAEI)

Cambridge Epigenetix is using epigenetics to reduce several routine & important diagnostic tests for common cancers to a simple blood draw.

About Cambridge Epigenetix Stock

Founded

2012

Industries

Software, Data and Analytics, Artificial Intelligence

Cambridge Epigenetix aims to change the way medicine is practiced by reducing several routine and important diagnostic screening and detection tests for colorectal cancer and other common tumours to a simple blood draw. CEGX is pioneering the field of clinical epigenetics, and the company’s technology has proven the link between the epigenetic DNA modification 5-hydroxymethylcytosine (5hmC) and disease. Research has revealed a wide range of diagnostic and prognostic applications for 5hmC, now one of the most important biomarkers in the quest to improve human health. Spun-out of the University of Cambridge in 2012, CEGX was founded to develop and commercialise the science of world leading researchers Professor Sir Shankar Balasubramanian, co-inventor of Solexa sequencing, and Professor Anjana Rao, who identified the essential role of the TET enzymes and 5hmC in development and disease. A privately held company headquartered in Cambridge, UK, Cambridge Epigenetix is supported by several high-profile investors: GV (Google Ventures), Sequoia, Syncona, New Science Ventures, Ahren Innovation Capital, DNA Capital and the University of Cambridge.

Cambridge Epigenetix Management

Leadership team at Cambridge Epigenetix

Co-Founder and Director

Shankar Balasubramian

Co-Founder and Director

Bobby Yerramilli-Rao

Locked Features

Join now and verify your accreditation status to gain access to:

  • Cambridge Epigenetix current valuation
  • Cambridge Epigenetix stock price
  • Available deals in Cambridge Epigenetix and all other companies
  • Deal offering documents
  • EquityZen's proprietary data and insights, including
    • Cap tables, which include funding history by Share Class and Liquidity Preferences
    • Company Highlights
    • Business Model
    • Risk Factors
Join Now

How to invest in Cambridge Epigenetix stock?

Accredited investors can buy pre-IPO stock in companies like Cambridge Epigenetix through EquityZen funds. These investments are made available by existing Cambridge Epigenetix shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.

How to sell Cambridge Epigenetix stock?

Shareholders can sell their Cambridge Epigenetix stock through EquityZen's private company marketplace. EquityZen's network includes over 320K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.

If I invest, how do I exit my investment?

There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.

Why choose EquityZen?

Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 42K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."